CPI-006 is an immunomodulatory antibody that binds to immune cells, leading to activation of B cells and antibody production that we believe will destroy the SARS-CoV-2 virus.

This therapy has the potential to be used in mild or moderately ill COVID-19 patients as well as in healthy people to enhance the efficacy of vaccines.

Increasing the immune response to the COVID-19 infection may lead to faster viral clearance, shorter recovery time, less complications and longer lasting immunity

This approach has the potential to be a foundational therapy for SARS-CoV-2 mutant variants, other coronaviruses or future pandemics